Edition:
India

Luye Pharma's Transdermal Patch Receives German Medical Regulatory Approval


Monday, 15 Jul 2019 

July 15 (Reuters) - Luye Pharma Group Ltd <2186.HK>::GROUP'S RIVASTIGMINE ONCE A DAY TRANSDERMAL PATCH APPROVED BY GERMAN FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES.GROUP ALSO DEVELOPING PATENTED RIVASTIGMINE MULTI-DAY TRANSDERMAL PATCH (LY30410), OFFERING NEW DOSAGE REGIMEN.RIVASTIGMINE ONCE A DAY TRANSDERMAL PATCH IN DOSAGE STRENGTH 13.3MG/24H APPROVED BY GERMAN FEDERAL INSTITUTE FOR DRUGS &MEDICAL DEVICES. 

Company Quote

6.09
 --
17 Oct 2019